Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model

Pharmacological Research

Volumn 62, Issue 6, 2010, Pages 514-522

  Macedo, Bárbara ^a   Magalhães, Joana ^a,b   Batista, Ana Rita ^a,b   Saraiva, Maria João ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Amyloid; Carvedilol; ER stress; Transthyretin; Treatment

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; AMYLOID; BIOLOGICAL MARKER; CARVEDILOL; OLIGOMER; PREALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; ENDOPLASMIC RETICULUM STRESS; FAMILIAL AMYLOID POLYNEUROPATHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NEUROBLASTOMA CELL; NEUROMODULATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SYMPTOMATOLOGY; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADRENERGIC BETA-ANTAGONISTS; AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CARBAZOLES; HUMANS; MICE; MICE, TRANSGENIC; OXIDATION-REDUCTION; OXIDATIVE STRESS; POLYNEUROPATHIES; PREALBUMIN; PROPANOLAMINES; PROTEIN MULTIMERIZATION;

EID: 78049528674     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.08.001     Document Type: Article

References (32)

1. Andrea T.A., Cavalieri R.R., Goldfine I.D., Jorgensen E.C. Binding of thyroid hormones and analogues to the human plasma protein prealbumin. Biochemistry 1980, 19:55-63.
2. Cardoso I., Goldsbury C.S., Muller S.A., Olivieri V., Wirtz S., Damas A.M., et al. Transthyretin fibrillogenesis entails the assembly of monomers, a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 2002, 317:683-685.
3. Ando Y., Nyhlin N., Suhr O., Holmgren G., Uchida K., el Sahly M., et al. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun 1997, 232:497-502.
4. Sousa M.M., Du Yan S., Fernandes R., Guimarães A., Stern D., Saraiva M.J. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001, 21:7576-7586.
5. Macedo B., Batista A.R., do Amaral J.B., Saraiva M.J. Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy. Mol Med 2007, 13:584-591.
6. Mariani E., Polidori M.C., Cherubini A., Meccoci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Anal Technol Biomed Life Sci 2005, 827:65-75.
7. Teixeira P.F., Cerca F., Santos S.D., Saraiva M.J. Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem 2006, 281:21998-22003.
8. Yue T.L., Cheng H.Y., Lysko P.G., McKenna P.J., Feuerstein R., Gu J.L., et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992, 263:92-98.
9. Abreu R.M., Santos D.J., Moreno A.J. Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress. J Pharmacol Exp Ther 2000, 295:1022-1030.
10. Noguchi N., Nishino K., Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem Pharmacol 2000, 59:1069-1076.
11. Feuerstein G.Z., Yue T.L., Cheng H.Y., Ruffolo R.R. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens 1993, (Suppl. 11):41-48.
12. Yue T.L., Wang X., Gu J.L., Ruffolom R.R., Feuerstein G.Z. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995, 273:1442-1449.
13. Naidu P.S., Singh A., Kulkarni S.K. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol 2002, 136:193-200.
14. Bieschke J., Zhang Q., Powers E.T., Lerner R.A., Kelly J.W. Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry 2005, 44:4977-4983.
15. Sousa M.M., Fernandes R., Palha J.A., Taboada A., Vieira P., Saraiva M.J. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 2002, 161:1935-1948.
16. Almeida M.R., Damas A.M., Lans M.C., Brower A., Saraiva M.J. Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine 1997, 6:309-315.
17. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
18. Almeida M.R., Macedo B., Cardoso I., Alves I., Valencia G., Arsequell G., et al. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J 2004, 381:351-356.
19. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
20. Altland K., Winter P., Sauerborn M.K. Electrically neutral microheterogeneity of human plasma transthyretin (prealbumin) detected by isoelectric focusing in urea gradients. Electrophoresis 1999, 20:1349-1364.
21. Yuan J., Yankner B.A. Apoptosis in the nervous system. Nature 2000, 407:802-809.
22. SuzukiY, Tanaka M., Sohmiya M., Yoshida T., Okamoto K. Antioxidant properties of carvedilol: inhibition of lipid peroxidation, protein oxidation and superoxide generation. Neurol Res 2003, 25:749-753.
23. Dyrks T., Dyrks E., Monning U., Urmoneit B., Turner J., Beyreuther K. Generation of beta 4A from the amyloid protein precursor and fragments. FEBS Lett 1993, 335:89-93.
24. Troncoso J.C., Costello A., Watson A.L., Johnson G.V. In vitro polymerization of oxidized tau into filaments. Brain Res 1993, 613:313-316.
25. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004, 3:205-214.
26. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
27. Howlett D.R., George A.R., Owen D.E., Ward R.V., Markwell R.E. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem J 1999, 343:419-423.
28. Wang N.S., Unkila M.T., Reineks E.Z., Distelhorst C.W. Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. J Biol Chem 2001, 276:44117-44128.
29. Macedo B., Batista A.R., Ferreira N., Almeida M.R., Saraiva M.J. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta 2008, 1782(9):517-522.
30. Suhr O.B., Lang K., Wikstrom L., Ando Y., El-Salhy M., Holmgren G., et al. Scavenger treatment of free radical injury in familial amyloidotic polyneuropathy: a study on Swedish transplanted and non-transplanted patients. Scand J Clin Lab Invest 2001, 61:11-18.
31. Ando Y. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med Mol Morphol 2005, 38:142-154.
32. Suhr O.B., Lindqvist P., Olofsson B.-O., Waldenstrom A., Backman C. Myocardial hypertrophy and function are related to age of onset in familial amyloidotic polyneuropathy. Amyloid 2006, 13:154-159.